
23andMe (ME) is a genetic testing company that provides individuals with their DNA-based ancestry records. This company has the second-largest ancestry database after AncestryDNA, but has been struggling due to waning demand for one-time-use DNA kits.
Moreover, a 2023 data breach exposed 6.9 million users’ data. The data breach eroded trust and led to a $30 million lawsuit settlement. By late 2024, 23andMe laid off 40% of its workforce and shuttered its drug development arm. ME stock then plunged below the Nasdaq $1 listing requirement, and all independent board members resigned over disagreements with CEO Anne Wojcicki’s privatization push.